Compare DNA & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNA | LXRX |
|---|---|---|
| Founded | 2008 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 607.1M | 547.4M |
| IPO Year | N/A | 2000 |
| Metric | DNA | LXRX |
|---|---|---|
| Price | $6.70 | $1.47 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $10.50 | $3.23 |
| AVG Volume (30 Days) | 978.5K | ★ 2.9M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $31,081,000.00 |
| Revenue This Year | N/A | $56.61 |
| Revenue Next Year | $3.07 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2481.48 |
| 52 Week Low | $5.00 | $0.28 |
| 52 Week High | $17.58 | $1.83 |
| Indicator | DNA | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 34.04 | 55.19 |
| Support Level | N/A | $1.07 |
| Resistance Level | $10.05 | $1.65 |
| Average True Range (ATR) | 0.71 | 0.09 |
| MACD | -0.14 | 0.02 |
| Stochastic Oscillator | 0.81 | 64.44 |
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.